Abstract
Smoking is one of the most serious but preventable causes of cardiovascular disease (CVD). Key aspects of pathological process associated with smoking include endothelial dysfunction, a prothrombotic state, inflammation, altered lipid metabolism, and hypoxia. Multiple molecular events are involved in smoking-induced CVD. However, the dysregulations of reactive oxygen species (ROS) generation and metabolism mainly contribute to the development of diverse CVDs, and NADPH oxidase (NOX) has been established as a source of ROS responsible for the pathogenesis of CVD. NOX activation and resultant ROS production by cigarette smoke (CS) treatment have been widely observed in isolated blood vessels and cultured vascular cells, including endothelial and smooth muscle cells. NOX-mediated oxidative stress has also been demonstrated in animal studies. Of the various NOX isoforms, NOX2 has been reported to mediate ROS generation by CS, but other isoforms were not tested thoroughly. Of the many CS constituents, nicotine, methyl vinyl ketone, and α,β-unsaturated aldehydes, such as, acrolein and crotonaldehyde, appear to be primarily responsible for NOX-mediated cytotoxicity, but additional validation will be needed. Human epidemiological studies have reported relationships between polymorphisms in the CYBA gene encoding p22phox, a catalytic subunit of NOX and susceptibility to smoking-related CVDs. In particular, G allele carriers of A640G and -930A/G polymorphisms were found to be vulnerable to smoking-induced cardiovascular toxicity, but results for C242T studies are conflicting. On the whole, evidence implicates the etiological role of NOX in smoking-induced CVD, but the clinical relevance of NOX activation by smoking and its contribution to CVD require further validation in human studies. A detailed understanding of the role of NOX would be helpful to assess the risk of smoking to human health, to define high-risk subgroups, and to develop strategies to prevent or treat smoking-induced CVD.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
White, W.B. (2007) Smoking-related morbidity and mortality in the cardiovascular setting. Prev. Cardiol., 10, 1–4.
Ezzati, M., Henley, S.J., Thun, M.J. and Lopez, A.D. (2005) Role of smoking in global and regional cardiovascular mortality. Circulation, 112, 489–497.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. (2014) 2014 Surgeon General’s Report: The Health Consequences of Smoking—50 Years of Progres. (Online). Available: http://www.surgeongeneral.gov/library/reports/50-years-of-progress/full-report.pdf (Aug. 10, 2014).
Zheng, W., McLerran, D.F., Rolland, B.A., Fu, Z., Boffetta, P., He, J., Gupta, P.C., Ramadas, K., Tsugane, S., Irie, F., Tamakoshi, A., Gao, Y.T., Koh, W.P., Shu, X.O., Ozasa, K., Nishino, Y., Tsuji, I., Tanaka, H., Chen, C.J., Yuan, J.M., Ahn, Y.O., Yoo, K.Y., Ahsan, H., Pan, W.H., Qiao, Y.L., Gu, D., Pednekar, M.S., Sauvaget, C., Sawada, N., Sairenchi, T., Yang, G., Wang, R., Xiang, Y.B., Ohishi, W., Kakizaki, M., Watanabe, T., Oze, I., You, S.L., Sugawara, Y., Butler, L.M., Kim, D.H., Park, S.K., Parvez, F., Chuang, S.Y., Fan, J.H., Shen, C.Y., Ghen, Y., Grant, E.J., Lee, J.E., Sinha, R., Matsuo, K., Thomguist, M., Inoue, M., Feng, Z., Kang, D. and Patter, J.D. (2014) Burden of total and cause-specific mortality related to tobacco smoking among adults aged ≥ 45 years in Asia: a pooled analysis of 21 cohorts. PLoS Med., 11, e1001631.
De Rosa, S., Pacileo, M., Sasso, L., Di Palma, V., Maietta, P., Paglia, A., Brevetti, L., Cirillo, P. and Chiariello, M. (2008) Insights into pathophysiology of smoke-related cardiovascular disease. Monaldi Arch. Chest Dis., 70, 59–67.
Orosz, Z., Csiszar, A., Labinskyy, N., Smith, K., Kaminski, P.M., Ferdinandy, P., Wolin, M.S., Rivera, A. and Ungvari, Z. (2007) Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: role of NAD(P)H oxidase activation. Am. J. Physiol. Heart Circ. Physiol., 292, H130–139.
Jiang, F., Zhang, Y. and Dusting, G.J. (2011) NADPH oxidasemediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol. Rev., 63, 218–242.
Bedard, K. and Krause, K.H. (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev., 87, 245–313.
Cave, A., Grieve, D., Johar, S., Zhang, M. and Shah, A.M. (2005) NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology. Philos. Trans. R. Soc. Lond B Biol. Sci., 360, 2327–2334.
Lassègue, B., San Martin, A. and Griendling, K.K. (2012) Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ. Res., 110, 1364–1390.
Jaimes, E.A., DeMaster, E.G., Tian, R.X. and Raij, L. (2004) Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. Arterioscler. Thromb. Vasc. Biol., 24, 1031–1036.
Haddad, P., Dussault, S., Groleau, J., Turgeon, J., Michaud, S.E., Ménard, C., Perez, G., Maingrette, F. and Rivard, A. (2009) Nox2-containing NADPH oxidase deficiency confers protection from hindlimb ischemia in conditions of increased oxidative stress. Arterioscler. Thromb. Vasc. Biol., 29, 1522–1528.
Steffen, Y., Vuillaume, G., Stolle, K., Roewer, K., Lietz, M., Schueller, J., Lebrun, S. and Wallerath, T. (2012) Cigarette smoke and LDL cooperate in reducing nitric oxide bioavailability in endothelial cells via effects on both eNOS and NADPH oxidase. Nitric Oxide, 27, 176–184.
Hotston, M.R., Jeremy, J.Y., Bloor, J., Koupparis, A., Persad, R. and Shukla, N. (2007) Sildenafil inhibits the up-regulation of phosphodiesterase type 5 elicited with nicotine and tumour necrosis factor-alpha in cavernosal vascular smooth muscle cells: mediation by superoxide. BJU Int., 99, 612–618.
Barbieri, S.S., Zacchi, E., Amadio, P., Gianellini, S., Mussoni, L., Weksler, B.B. and Tremoli, E. (2011) Cytokines present in smokers’ serum interact with smoke components to enhance endothelial dysfunction. Cardiovasc. Res., 90, 475–483.
Barbieri, S.S., Amadio, P., Gianellini, S., Zacchi, E., Weksler, B.B. and Tremoli, E. (2011) Tobacco smoke regulates the expression and activity of microsomal prostaglandin E synthase-1: role of prostacyclin and NADPH-oxidase. FASEB J., 25, 3731–3740.
Noya, Y., Seki, K., Asano, H., Mai, Y., Horinouchi, T., Higashi, T., Terada, K., Hatate, C., Hoshi, A., Nepal, P., Horiguchi, M., Kuge, Y. and Miwa, S. (2013) Identification of stable cytotoxic factors in the gas phase extract of cigarette smoke and pharmacological characterization of their cytotoxicity. Toxicology, 314, 1–10.
Pei, Z., Zhuang, Z., Sang, H., Wu, Z., Meng, R., He, E.Y., Scott, G.I., Maris, J.R., Li, R. and Ren, J. (2014) alpha,beta-Unsaturated aldehyde crotonaldehyde triggers cardiomyocyte contractile dysfunction: role of TRPV1 and mitochondrial function. Pharmacol. Res., 82, 40–50.
Messner, B. and Bernhard, D. (2014) Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler. Thromb. Vasc. Biol., 34, 509–515.
Rafacho, B.P., Azevedo, P.S., Polegato, B.F., Fernandes, A.A., Bertoline, M.A., Fernandes, D.C., Chiuso-Minicucci, F., Roscani, M.G., Dos Santos, P.P., Matsubara, L.S. Matsubara, B.B., Laurindo, F.R., Paiva, S.A., Zornoff, L.A. and Minicucci, M.F. (2011) Tobacco smoke induces ventricular remodeling associated with an increase in NADPH oxidase activity. Cell. Physiol. Biochem., 27, 305–312.
Xiao, D., Huang, X., Yang, S. and Zhang, L. (2011) Antenatal nicotine induces heightened oxidative stress and vascular dysfunction in rat offspring. Br. J. Pharmacol., 164, 1400–1409.
Loffredo, L., Carnevale, R., Perri, L., Catasca, E., Augelletti, T., Cangemi, R., Albanese, F., Piccheri, C., Nocella, C., Pignatelli, P. and Violi, F. (2011) NOX2-mediated arterial dysfunction in smokers: acute effect of dark chocolate. Heart, 97, 1776–1781.
Carnevale, R., Loffredo, L., Pignatelli, P., Nocella, C., Bartimoccia, S., Di Santo, S., Martino, F., Catasca, E., Perri, L. and Violi, F. (2012) Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers. J. Thromb. Haemostasis, 10, 125–132.
Barua, R.S. and Ambrose, J.A. (2013) Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler. Thromb. Vasc. Biol., 33, 1460–1467.
Breitling, L.P. (2013) Current genetics and epigenetics of smoking/tobacco-related cardiovascular disease. Arterioscler. Thromb. Vasc. Biol., 33, 1468–1472.
San José, G., Fortuño, A., Beloqui, O., Díez, J. and Zalba, G. (2008) NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clin. Sci. (Lond), 114, 173–182.
Niemiec, P., Nowak, T., Balcerzyk, A., Krauze, J. and Zak, I. (2011) The CYBA gene A640G polymorphism influences predispositions to coronary artery disease through interactions with cigarette smoking and hypercholesterolemia. Biomarkers, 16, 405–412.
Niemiec, P., Nowak, T., Iwanicki, T., Krauze, J., Gorczynska-Kosiorz, S., Grzeszczak, W., Ochalska-Tyka, A. and Zak, I. (2014) The -930A>G polymorphism of the CYBA gene is associated with premature coronary artery disease. A case-control study and gene-risk factors interactions. Mol. Biol. Rep., 41, 3287–3294.
Fan, M., Raitakari, O.T., Kahönen, M., Juonala, M., Hutri-Kahonen, N., Pörsti, I., Viikari, J. and Lehtimäki, T. (2009) The association between cigarette smoking and carotid intima-media thickness is influenced by the -930A/G CYBA gene polymorphism: the Cardiovascular Risk in Young Finns Study. Am. J. Hypertens., 22, 281–287.
Raitakari, O.T. (1999) Imaging of subclinical atherosclerosis in children and young adults. Ann. Med., 31 Suppl 1, 33–40.
Fan, M., Raitakari, O.T., Kähönen, M., Juonala, M., Hutri-Kähönen, N., Marniemi, J., Rontu, R., Pörsti, I., Viikari, J. and Lehtimäki, T. (2007) CYBA C242T gene polymorphism and flow-mediated vasodilation in a population of young adults: the Cardiovascular Risk in Young Finns Study. J. Hypertens., 25, 1381–1387.
Ge, J., Ding, Z., Song, Y. and Wang, F. (2012) Smoking dose modifies the association between C242T polymorphism and prevalence of metabolic syndrome in a Chinese population. PLoS One, 7, e31926.
He, M.A., Cheng, L.X., Jiang, C.Z., Zeng, H.S., Wang, J., Wang, F., Chen, Y., Yang, M., Tan, H., Zheng, H.Y., Hu, F.B. and Wu, T.C. (2007) Associations of polymorphism of P22(phox) C242T, plasma levels of vitamin E, and smoking with coronary heart disease in China. Am. Heart J., 153, 640 e1–6.
Ueno, T., Watanabe, H., Fukuda, N., Tsunemi, A., Tahira, K., Matsumoto, T., Takayama, T., Chiku, M., Saito, S., Sato, Y. Hirayama, A., Matsumoto, K. and Soma, M. (2009) Influence of genetic polymorphisms in oxidative stress related genes and smoking on plasma MDA-LDL, soluble CD40 ligand, E-selectin and soluble ICAM1 levels in patients with coronary artery disease. Med. Sci. Monit., 15, CR341–348.
Niemiec, P., Zak, I. and Wita, K. (2007) The 242T variant of the CYBA gene polymorphism increases the risk of coronary artery disease associated with cigarette smoking and hypercholesterolemia. Coron. Artery Dis., 18, 339–346.
Xiao, D., Huang, X., Yang, S. and Zhang, L. (2013) Estrogen normalizes perinatal nicotine-induced hypertensive responses in adult female rat offspring. Hypertension, 61, 1246–1254.
Drummond, G.R., Selemidis, S., Griendling, K.K. and Sobey, C.G. (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discovery, 10, 453–471.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Kim, M., Han, Ch. & Lee, MY. NADPH Oxidase and the Cardiovascular Toxicity Associated with Smoking. Toxicol Res. 30, 149–157 (2014). https://doi.org/10.5487/TR.2014.30.3.149
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2014.30.3.149